Sparks commentary

Healthcare

Sparks

BioArctic (Nasdaq Stockholm: BIOA B) enters global license agreement with BMS
Published by Arron Aatkar

The agreement with Bristol Myers Squibb (BMS) is for BioArctic’s PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody programme, which includes the candidates BAN1503 and BAN2803, the latter of which covers BioArctic’s BrainTransporter technology. Deal terms include an upfront payment of US$100m and up to US$1.25bn in milestone payments, alongside low double-digit percentage royalties on global product sales.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free